Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.
Member in Photos
Member in the News
Incyte has first drug, Jakafi, approved by the FDA for patience with Myelofibrosis
Incyte Corporation announced that it has earned a $15 million payment from Novartis based on the achievement of a predefined milestone in an ongoing Phase I dose
Incyte’s experimental blood cancer treatment, ruxolitinib, has delivered in another Phase III trial, this one led by co-developer Novartis in Europe.